Altered effects of angiotensin II type 1 and type 2 receptor blockers on cardiac norepinephrine release and inotropic responses during cardiac sympathetic nerve stimulation in aorto-caval shant rats

Circulation Journal

Volumn 68, Issue 7, 2004, Pages 683-690

  Suzuki, Hitoshi ^a   Maehara, Kazuhira ^a   Yaoita, Hiroyuki ^a   Maruyama, Yukio ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin; Cardiac hypertrophy; Sympathetic nervous system

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; LOSARTAN; NORADRENALIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTOCAVAL FISTULA; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INFUSION; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART PERFUSION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; INOTROPISM; MALE; NONHUMAN; NORADRENALIN RELEASE; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHUNTING; SYMPATHETIC NERVE; SYMPATHETIC TONE;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AORTA, ABDOMINAL; ARTERIOVENOUS SHUNT, SURGICAL; ECHOCARDIOGRAPHY; HEART; HEART CONDUCTION SYSTEM; IMIDAZOLES; MALE; MYOCARDIAL CONTRACTION; NOREPINEPHRINE; PYRIDINES; RATS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; REFERENCE VALUES; VENA CAVA, INFERIOR; VENTRICULAR FUNCTION, LEFT;

EID: 3142588800     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.68.683     Document Type: Article

References (28)

1. Patel AR, Konstam MA. Recent advances in the treatment of heart failure. Circ J 2002; 66: 117-121.
2. Katz AM. Proliferative signaling and disease progression in heart failure. Circ J 2002; 66: 225-231.
3. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
4. Cohn JN, Tognonin G for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
5. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 2003; 362: 759-766.
6. Baker KM, Aceto JF. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol 1990; 259: H610-H618.
7. Kojima M, Shiojima I, Yamazaki T, Komuro I, Yunzeng Z, Ying W, et al. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. Circulation 1994; 89: 2204-2211.
8. Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, et al for the Losartan Hemodynamic Study Group. Losartan in heart failure: Hemodynamic effects and tolerability. Circulation 1995; 91: 691-697.
9. Gilbert EM, Sandoval A, Larrabee P, Renlund DG, O'Connell JB, Bristow MR. Lisinopril lowers cardiac adrenergic drive and increases β-receptor density in the failing human heart. Circulation 1993; 88: 472-480.
10. Latini R, Masson S, Anand I, Judd D, Maggioni, Chiang YT, et al for the Val-HeFT Investigators. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: The valsartan heart failure trial (Val-HeFT). Circulation 2002; 106: 2454-2458.
11. Brasch H, Sieroslawski L, Dominiak P. Angiotensin II increases norepinephrine release from atria by acting on angiotensin subtype I receptors. Hypertension 1993; 22: 699-704.
12. Cheng CP, Suzuki M, Ohte N, Ohno M, Wang ZM, Little WC. Altered ventricular and myocyte response to angiotensin II in pacing-induced heart failure. Circ Res 1996; 78: 880-892.
13. Oikawa Y, Maehara K, Saito T, Tamagawa K, Maruyama Y. Attenuation of angiotensin II-mediated coronary vasoconstriction and vasodilatory action of angiotensin-converting enzyme inhibitor in pacing-induced heart failure in dogs. J Am Coll Cardiol 2001; 38: 1188-1194.
14. Schwartz DD, Naff BP. Activation of protein kinase C by angiotensin II decreases β1-adrenergic receptor responsiveness in the rat heart. J Cardiovasc Pharmacol 1997; 29: 257-264.
15. Onuki N, Takahashi H, Suzuki H, Saito T, Maehara K, Maruyama Y. Dissociation of chronotropic and inotropic responses in the rat heart during sympathetic stimulation. Jpn Circ J 1999; 63: 710-717.
16. Takahashi H, Maehara K, Onuki N, Saito T, Maruyama Y. Decreased contractility of the left ventricle is induced by neurotransmitter acetylcholine, but not by vagal stimulation in rats. Jpn Heart J 2003; 44: 257-270.
17. Balt JC, Mathy MJ, Nap A, Pfaffendorf M, van Zwieten PA. Involvement of the AT2-receptor in angiotensin II-induced facilitation of sympathetic neurotransmission. J Renin Angiotensin Alelosterone Syst 2002; 3: 181-187.
18. Garcia R, Diebold S. Simple, rapid, and effective method of producing aortocaval shunts in the rat. Cardiovasc Res 1990; 24: 430-432.
19. Kamosinska B, Nowicki D, Szulczyk A, Szulczyk P. Spinal segmental sympathetic outflow to cervical sympathetic trunk, vertebral nerve, inferior cardiac nerve and sympathetic fibres in the thoracic vagus. J Auton Nerv Syst 1991; 32: 199-204.
20. Hunyady L, Balla T, Catt K. The ligand binding site of the angiotensin AT1 receptor. Trends Phamacol Sci 1996; 17: 135-140.
21. Yaoita H, Sakabe A, Maehara K, Maruyama Y. Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats. Circulation 2002; 105: 975-980.
22. Bohm M, Gierschik P, Jakobs KH, Pieske B, Schnabel P, Ungerer M, et al. Increase of Gi α in human hearts with dilated but not ischemic cardiomyopathy. Circulation 1990; 82: 1249-1265.
23. Ruzicka M, Yuan B, Leenen FHH. Efffects of enalapril versus losartan on regression of volume overload-induced cardiac hypertrophy in rats. Circulation 1994; 90: 484-491.
24. Poole TD, Holder MS, Gipson D. Cardiac angiotensin II receptor populations during aortocaval fistula, AII and β adrenergic receptor blockade. Biochem Biophys Res Commun 1994; 203: 1865-1874.
25. 123I-MIBG uptake in patients with chronic heart failure. J Nucl Med 2003; 44: 1618-1624.
26. Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992; 33: 471-477.
27. Cohen-Solal A, Esanu Y, Logeart D, Pessione F, Dubois C, Dreyfus G, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: Relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol 1999; 33: 759-766.
28. Rundqvist B, Eisenhofer G, Elam M, Friberg P. Attenuated cardiac sympathetic responsiveness during dynamic exercise in patients with heart failure. Circulation 1997; 95: 940-945.